Ficlatuzumab
- Generic Name
- Ficlatuzumab
- Drug Type
- Biotech
- CAS Number
- 1174900-84-5
- Unique Ingredient Identifier
- 77E89833TG
- Background
Ficlatuzumab has been used in trials studying the treatment of Acute Myeloid Leukemia, Non-small Cell Lung Cancer, Mullerian Mixed Tumor of Ovary, Relapsed Acute Myeloid Leukemia, and Refractory Acute Myeloid Leukemia, among others.
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- Conditions
- Metastatic Head-and-neck Squamous-cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-10-03
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 410
- Registration Number
- NCT06064877
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of California Los Angeles, Westwood, California, United States
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
- Conditions
- Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaStage IVB Lip and Oral Cavity Squamous Cell CarcinomaStage IVB Nasal Cavity and Paranasal Sinus Squamous Cell CarcinomaStage IVC Lip and Oral Cavity Squamous Cell CarcinomaStage IVA Nasopharyngeal Keratinizing Squamous Cell CarcinomaStage IVA Oropharyngeal Squamous Cell CarcinomaStage IVC Oropharyngeal Squamous Cell CarcinomaHead and Neck Basaloid CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Biological: Cetuximab
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 78
- Registration Number
- NCT03422536
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2021-08-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 26
- Registration Number
- NCT03316599
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02318368
- Locations
- 🇦🇺
Frankston Hospital, Frankston, Victoria, Australia
🇮🇹IRCCS Ospedale S.Raffaele, Milano, Italy
🇮🇹IRCCS Istituto Clinico Humanitas, Rozzano MI, Italy
Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma
- Conditions
- Carcinoma, Squamous Cell of Head and Neck
- Interventions
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- Julie E. Bauman, MD, MPH
- Target Recruit Count
- 1
- Registration Number
- NCT02277184
- Locations
- 🇺🇸
UPMC Presbyterian, Pittsburgh, Pennsylvania, United States
🇺🇸Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸UPMC Shadyside, Pittsburgh, Pennsylvania, United States
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- Conditions
- Carcinoma, Squamous Cell of Head and NeckSquamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma, Head And Neck
- Interventions
- First Posted Date
- 2014-10-28
- Last Posted Date
- 2019-04-18
- Lead Sponsor
- James J Lee
- Target Recruit Count
- 14
- Registration Number
- NCT02277197
- Locations
- 🇺🇸
UPMC Shadyside, Pittsburgh, Pennsylvania, United States
🇺🇸UPMC Presbyterian, Pittsburgh, Pennsylvania, United States
🇺🇸Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
- Conditions
- Relapsed Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2014-04-10
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- C. Babis Andreadis
- Target Recruit Count
- 17
- Registration Number
- NCT02109627
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient
- Conditions
- Mullerian Mixed Tumor of Ovary
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2015-07-29
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Registration Number
- NCT02090127
- Locations
- 🇺🇸
START, San Antonio, Texas, United States
SCH-900105 in Recurrent Glioblastoma
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT01189513
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.